^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
BAL0891
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Basilea, Crossfire Oncology, SillaJen
Drug class:
PLK1 inhibitor, TTK inhibitor
Related drugs:
